Compare GILT & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GILT | WVE |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | Israel | Singapore |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1997 | 2015 |
| Metric | GILT | WVE |
|---|---|---|
| Price | $12.88 | $6.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 16 |
| Target Price | $19.00 | ★ $29.81 |
| AVG Volume (30 Days) | 843.5K | ★ 3.4M |
| Earning Date | 05-13-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,704,000.00 |
| Revenue This Year | $15.06 | N/A |
| Revenue Next Year | $11.72 | $85.67 |
| P/E Ratio | $42.82 | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $7.01 | $5.02 |
| 52 Week High | $20.99 | $21.73 |
| Indicator | GILT | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 41.24 | 53.69 |
| Support Level | $11.28 | $6.02 |
| Resistance Level | $13.43 | $6.31 |
| Average True Range (ATR) | 0.82 | 0.29 |
| MACD | 0.10 | 0.07 |
| Stochastic Oscillator | 31.14 | 92.16 |
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company operates in three operating segments: Gilat Commercial Division, Gilat Defense Division, and Gilat Peru Division. The majority of its revenue is generated from the Gilat Commercial segment.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.